Cost—Effective Prescribing in Elderly People D. J. Richard MorganCarol A. SuttersBrian Livesley Leading Article 15 November 2012 Pages: 387 - 393
Health—Related Quality of Life Assessment and the Pharmaceutical Industry Dennis A. RevickiMargaret RothmanBryan Luce Review Article 15 November 2012 Pages: 394 - 408
Pharmacoeconomics of Antibacterial Treatment Peter G. DaveyMo M. MalekSharon E. Parker Review Article 15 November 2012 Pages: 409 - 437
Cost—Utility Analysis of Early Thrombolytic Therapy D. CastielC. HervéM. Soula Original Research Article 15 November 2012 Pages: 438 - 442
Imipenem/Cilastatin Paul BenfieldPaul Chrisp Pharmacoeconomic Drug Evaluation 15 November 2012 Pages: 443 - 459
β—Blockers vs Calcium Channel Blockers vs ACE Inhibitors Dahlof CDimenas EJ. Boelaert Current Comment 15 November 2012 Pages: 460 - 462
Should Indirect Costs and Benefits be Included? David A. Henry Correspondence 15 November 2012 Pages: 462 - 462